GCM
ADCT icon

Gladius Capital Management’s ADC Therapeutics ADCT Stock Holding History

Gladius Capital Management’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-19,752
Closed -$17.7K – 318
2023
Q3 		$17.7K Buy
+19,752
New +$26.3K ﹤0.01% 342

Other funds holding ADCT

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
VCG
Vantage Consulting Group Virginia Beach, Virginia $19.7M AUM 280.87% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

Gladius Capital Management's ADCT Position: Q4 2023 in Review

Gladius Capital Management sold out of ADC Therapeutics (ADCT) in Q4 2023, closing a stake of 19,752 shares — an estimated $17.7K sold.

Gladius Capital Management first reported a position in ADCT in Q3 2023 and held it in 1 quarter. The position peaked at $17.7K in Q3 2023. 37 funds tracked by Wall St. Rank hold ADCT as of Q4 2023.

  • Gladius Capital Management reported no remaining ADC Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Gladius Capital Management sold 19,752 ADC Therapeutics shares in Q4 2023, an estimated $17.7K.
  • Gladius Capital Management first reported a position in ADC Therapeutics in Q3 2023 and held it in 1 quarter.
  • Gladius Capital Management's ADC Therapeutics position peaked at $17.7K in Q3 2023.
  • 37 funds tracked by Wall St. Rank held ADC Therapeutics as of Q4 2023.

Based on Gladius Capital Management's 13F filing for Q4 2023, filed 7 Feb 2024.